Skip to main content
Fig. 4 | BMC Genomics

Fig. 4

From: Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Fig. 4

Validation of target kinases by inhibitors. a left panel: HCC-827 and CHP-212 cells were treated with indicated concentrations of CHEK1 inhibitor AZD7762 for 72 h. Then, cell viability was measured by Cell Titer Glo according to the manufacturer’s instructions. Middle panel: Fold changes for three independent sgRNAs for CHEK1 inhibitor AZD7762 are depicted at time point day 14. b Same as a) but CDK1,2,5,7,9 inhibitor and respective sgRNAs are shown. c Same as a) but AKT1/2/inhibitor MK2206 and respective sgRNAs are shown. d Same as a) but FGFR inhibitor BGJ398 and respective sgRNAs are shown. e Same as a) but BRAF inhibitor Vemurafenib and respective sgRNAs are shown

Back to article page